StemCells (STEM) Awarded $20M from California Institute for Regenerative Medicine
Tweet
Share
E-mailGet Alerts STEM Hot Sheet
Down)Join SI Premium – FREE
StemCells, Inc. (Nasdaq: STEM) announced after the close Thursday that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company and its collaborators for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05).
The award is to fund preclinical development of StemCells' proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a potential treatment for cervical spinal cord injury.
The award is to fund preclinical development of StemCells' proprietary HuCNS-SC® product candidate (purified human neural stem cells) as a potential treatment for cervical spinal cord injury.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
- T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024
- Unilever (UL) shares jump as sales growth accelerate in Q1
Create E-mail Alert Related Categories
Corporate News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
